Trials / Terminated
TerminatedNCT05316116
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
A Pilot Study of Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Siltuximab | Siltuximab will be given on day 1 of each cycle. The dose will be 11 mg/kg given over 1 hour by intravenous infusion. Each cycle is three weeks (+-3 days). |
Timeline
- Start date
- 2023-02-15
- Primary completion
- 2024-10-18
- Completion
- 2024-10-18
- First posted
- 2022-04-07
- Last updated
- 2026-02-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05316116. Inclusion in this directory is not an endorsement.